Chronic Kidney Disease (CKD) is a progressive condition characterized by structural and functional abnormalities in the kidneys that persist for at least 3 months and are not reversible. With a global prevalence of 11% to 13% and 11% in Peru, CKD is a silent disease that can lead to complications such as anemia due to the shortened lifespan of red blood cells, alterations in iron metabolism, and reduced erythropoietin. The use of sodium-glucose cotransporter type 2 inhibitors (SGLT2 inhibitors) has sparked interest in CKD management. Studies such as DAPA-CKD and EMPA-KIDNEY have shown that SGLT2 inhibitors improve renal and cardiovascular parameters, increasing hemoglobin levels by 0.6 g/dl. This effect is attributed to improved erythropoiesis and efficient iron utilization through hepcidin reduction. Additionally, these inhibitors reduce oxidative stress and improve nitric oxide availab...